Clinical Trials Browser

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Carcinoma, Hepatocellular

Colonic Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Colonic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms

Brain Neoplasms

Endometrial Neoplasms

Locally Advanced Rectal Cancer (LARC)

Rectal Neoplasms

Uterine Cervical Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Rectal Neoplasms

Endometrial Neoplasms

Penile Neoplasms

Neoplasm Metastasis, Neoplasms, Sarcoma, Adrenocortical Carcinoma, Carcinoma, Neuroendocrine

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

Rectal Neoplasms

Multiple Myeloma

Breast Neoplasms, Triple Negative Breast Neoplasms

Endometrial Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Breast Neoplasms

Carcinoma, Endometrial Neoplasms

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

MMRd/MSI-H Stage II-III Endometrial Cancer

Colonic Neoplasms

Uterine Cervical Neoplasms

Clinical Trials

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

AZUR-4

I-SPY

Superhero

BeeHive

STAR

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

IMMUNOSTAR

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma

Dostarlimab and Cobolimab in Advanced Cervical Cancer

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

AZUR-1

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Pan-MSI-ACSE

NIRADO

China AZUR-1

DREAMM5

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

NADiR

RODEO

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

RUBY-J

OPAL

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

DOVE

NADIA

NAIO

ATOMICC